Development of the world's first humanized heart failure model AstraZeneca cooperation

Today, novoheart announced a R & D cooperation with AstraZeneca The two sides will jointly develop the world's first humanized model of extracorporeal ejection fraction preserved heart failure (HFPEF), providing a unique solution for the evaluation of new therapies Heart failure is a global epidemic In 2017 alone, there were an estimated 64.3 million cases worldwide, with an increasing prevalence The financial burden of medical care is more than 100 billion US dollars every year At present, the number of HFPEF patients accounts for about half of the number of heart failure cases, which is a global public health problem The disease is particularly common in the elderly and women According to statistics, the prevalence of heart failure in women over 80 years old is close to 10% Because of the complexity of etiology and pathological mechanism of HFPEF, the available disease models (including various animal models) are not ideal in simulating clinical manifestations of HFPEF Therefore, drug developers lack of effective tools for preclinical testing of candidate drug therapies, resulting in no effective progress in the clinical efficacy of HFPEF in the past few decades, nor effective therapies According to the press release, the 3D human heart cavity (hvcoc) technology, also known as "human heart in a jar", is the only human engineered heart tissue on the market that can perform clinical evaluation on the performance of human heart pump (including ejection fraction and formation pressure), which can reproduce the key phenotypic characteristics of HFPEF Unlike animal models, artificial hvcoc can be constructed using specific cells, matrix components, and patient specific human induced pluripotent stem cells (IPSC), so that the physical and mechanical properties of the model can be controlled artificially to simulate what is observed in the heart of HFPEF patients This model can be combined with the proprietary software and hardware of Zaixin company, which provides a unique analysis method for revealing the pathological mechanism of HFPEF and identifying new therapeutic targets, and can also be used to evaluate new therapies for HFPEF Photo source: Zaixin company website According to the terms of the agreement, Zaixin will cooperate with AstraZeneca's cardiovascular, renal and metabolic treatment departments to establish a new in vitro model to reproduce the key phenotypic characteristics of HFPEF using Zaixin's hvcoc technology Zaixin will have the exclusive intellectual property rights of the new HFPEF hvcoc model "AstraZeneca is committed to bringing new treatments to patients with heart failure," said Dr Kevin Costa, chief scientific officer of reoxin "We are looking forward to building this new HFPEF hvcoc model into a new tool that can fight heart failure around the world." "HFPEF patients have highly unmet treatment needs," said Regina fritsche, senior vice president and head of cardiovascular, renal and metabolic research and development at AstraZeneca Ms Danielson said: "by combining the revascularization specific hvcoc model with our expertise in heart failure, we will jointly create the first in vitro model that can reproduce the phenotypic characteristics of HFPEF to close the gap between the animal in vivo model and clinical trials And by providing preclinical data for humans, we can accelerate the development of drugs " (the original text has been deleted) reference material: [1] Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca, Retrieved November 26, 2019, from http:// A kind of